About

The Idea

Xinnate is a biopharmaceutical development company built on groundbreaking scientific research on innate immune mechanisms – evolutionary conserved biological systems with the purpose of keeping us healthy. One of these mechanisms involves natural defence peptides shown to be an effective and unique way of reducing excessive inflammation as well as preventing infection.

Xinnate specializes in drug development of proprietary peptides based on this pioneering technology of immune modulation for prevention and treatment of inflammation and infection within the areas skin and wounds, surgical materials and biomaterials. Xinnate’s first and primary focus is to develop a novel treatment for patients suffering from the rare and devastating skin disease Epidermolysis Bullosa (EB).

The company was founded in 2019 and is based on +15 years of world class research from Lund University.

The Concept

The primary drug candidate is based on the proprietary peptide, called TCP-25, that targets dysfunctional healing by controlling presence of microbials and the complex interplay of inflammatory responses. TCP-25 is part of the human natural defence system and can be used to address a range of different medical needs – a platform for drug development.

TCP-25 Gel is the product candidate with TCP-25 as the active pharmaceutical ingredient designed for treatment of inflammatory skin conditions. The unique advantages of TCP-25 Gel for wounds and inflammatory skin conditions are:

  • Anti-inflammatory: TCP-25 modulates inflammation, maintaining an optimal balance between healthy levels and mitigating excessive harmful inflammation.
  • Anti-infective: TCP-25 is effective against both gram-positive and gram-negative bacterial while preserving the commensal flora. In addition, TCP-25 demonstrates efficacy against antibiotic-resistant bacteria and fungi, enhancing its utility in combating infections.
  • Exudation: TCP-25 reduces the wound exudation, improving the wound environment and healing.
  • Sustainability: TCP-25, being a natural peptide sequence, ensures both patient and environmental safety.

Strategy

Xinnate executes an ambitious clinical development program for TCP-25 Gel with a clear focus on patients with Epidermolysis bullosa (EB). The safety, tolerability and preliminary efficacy have been demonstrated in a completed phase 1 program which included healthy volunteers with induced wounds, patients with large complex wounds (VLU) and patients with Epidermolysis bullosa (EB) wounds. The next step will be a randomized controlled phase 2 study in EB-patients to further address the safety and efficacy of TCP-25 Gel.

The overarching strategy involves leveraging the TCP-25 platform to expand and develop a diverse portfolio of applications. The aim is to advance each concept to a stage where commercial deals with larger pharmaceutical companies possessing global presence can be achieved. These transactions may involve out-licensing, partnering, licensing, strategic partnerships, joint ventures, or the sale of assets.